Literature DB >> 19116088

Circulating tumor cells as a potential efficacy end point in clinical trials of hormone-resistant prostate cancer.

Samir S Taneja.   

Abstract

Entities:  

Year:  2009        PMID： 19116088     DOI： 10.1007/s11934-009-0002-2

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


× No keyword cloud information.
  4 in total

1.  Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.

Authors:  Daniel F Hayes; Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; M Craig Miller; Jeri Matera; W Jeffrey Allard; Gerald V Doyle; Leon W W M Terstappen
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

2.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

3.  Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.

Authors:  D Olmos; H-T Arkenau; J E Ang; I Ledaki; G Attard; C P Carden; A H M Reid; R A'Hern; P C Fong; N B Oomen; R Molife; D Dearnaley; C Parker; L W M M Terstappen; J S de Bono
Journal:  Ann Oncol       Date:  2008-08-11       Impact factor: 32.976

4.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

Authors:  Steven J Cohen; Cornelis J A Punt; Nicholas Iannotti; Bruce H Saidman; Kert D Sabbath; Nashat Y Gabrail; Joel Picus; Michael Morse; Edith Mitchell; M Craig Miller; Gerald V Doyle; Henk Tissing; Leon W M M Terstappen; Neal J Meropol
Journal:  J Clin Oncol       Date:  2008-07-01       Impact factor: 44.544
  4 in total
  1 in total

1.  Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer.

Authors:  Sumanta Kumar Pal; Oliver Sartor
Journal:  Asian J Androl       Date:  2011-05-23       Impact factor: 3.285
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.